ASND · available-data snapshot
Ascendis Pharma A/S (ASND): Available-Data Snapshot
TickerWorth does not publish a DCF fair value for Ascendis Pharma A/S (ASND); the reason is set out below. What its filings and market data do show is below. The snapshot also sets out its trading multiples against 5 peers. Snapshot as of Oct 19, 2026.
Model by Miraaj Patel · generated from public market data · Updated Oct 19, 2026 · How these pages are made
Why is there no fair value for ASND?
We do not publish a fair value for Ascendis Pharma A/S. What we can say from its filings and market data is below.
What is ASND's TickerWorth Score?
Middle of the pack — real strengths and real weaknesses
Compared with Healthcare companies in US
Its strongest point: a profitable, high-quality business. Its weakest: trades above our estimate of what it's worth.
- Value · 30 of 100
Cheaper than 30% of Healthcare companies in US
- Price vs worth · 4 of 100
- Quality · 99 of 100
More profitable than virtually every one of the Healthcare companies in US
- Financial health · 69 of 100
Financially stronger than 69% of Healthcare companies in US
- Growth · 50 of 100
Growing faster than 50% of Healthcare companies in US
- Momentum · 44 of 100
Outperformed 44% of Healthcare companies in US over the past year
Confidence: Medium confidence · Scored
Get the Undervalued Company of the Week.
- Price
- $229.91
- Market cap
- $15,
128, 586, 240 - 52-week high
- $282.15
- 52-week low
- $186.05
- Currency
- USD
- Exchange
- NasdaqGS
Snapshot of Oct 19, 2026, quote time not published · Prices are delayed.
What we can say
We don't publish a discounted-cash-flow fair value for Ascendis Pharma A/S (ASND) because the free data sources we rely on don't expose the multi-year financials a DCF needs — common for small or thinly-covered listings. Rather than invent numbers, this page shows an honest snapshot of what the public data does support: the current price and size, any relative valuation multiples that exist, a book-value view, and a price-based read. Treat it as a descriptive starting point, not a valuation and not investment advice.
Read the full reasoning
On the numbers we do have, ASND trades at a recent price of $229.91, a market capitalisation of about $15,128,586,240, sitting 46% of the way up its 52-week range ($186.05–$282.15), on the NasdaqGS.
The standard alternative to a DCF is relative valuation — comparing ASND's trading multiples against a sector benchmark. Here that gives P/E of 17.6× (cheaper than the peer median of 41.9×); Fwd P/E of 21.3× (richer than the peer median of 17.5×); P/B of 9.4× (richer than the peer median of 7.8×); P/S of 14.4× (richer than the peer median of 6.2×); EV/EBITDA of 54.8× (richer than the peer median of 18.5×). A cheaper multiple than peers can flag a discount or a market that expects weaker growth; it is a comparison, not a recommendation.
The asset, or book-value, lens is the classic tool for asset-heavy businesses and financials. ASND shows a price-to-book (P/B) of 9.36 and book value of $24.57 per share. Price-to-book compares the market price to the accounting net-asset value per share; below 1.0 can mean a discount to net assets or that the market is pricing in trouble — descriptive either way, never a buy signal on its own.
Finally, a price-based read — explicitly not a valuation. ASND is in a mixed trend, trading -18.5% from its 52-week high. Over the past year the stock is +9.8%. Moving-average trend and 52-week position describe where the stock has traded; they say nothing about what it is worth.
ASND vs peers
Sector benchmark (bellwethers, not direct competitors).
| Multiple | ASND | Peer median | Read |
|---|---|---|---|
| P/E | 17.6× | 41.9× | cheaper than |
| Fwd P/E | 21.3× | 17.5× | richer than |
| P/B | 9.4× | 7.8× | richer than |
| P/S | 14.4× | 6.2× | richer than |
| EV/EBITDA | 54.8× | 18.5× | richer than |
What does Ascendis Pharma A/S do?
What does it do?
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It operates in the Biotechnology industry (Healthcare sector), headquartered in Denmark. The company employs roughly 1,189 people.
How does it make money?
The business turns $1.0B in annual revenue into profit. Out of every $100 of sales, about $65 is left as operating profit (operating margin of 65.0%), after a 91% gross margin on the products/services it sells. After all costs, taxes and interest, 70.8% of revenue becomes bottom-line net profit.
Is it financially healthy?
Financially it looks solid: carries modest debt (0.3× equity), comfortably covers its short-term bills (3.0× current ratio), and is currently profitable.
Who at ASND filed insider trades?
| Date | Insider | Relationship | What happened | Value | Filing |
|---|---|---|---|---|---|
| Bodenhoff Mads | SVP & PAO | Option exercise | $330,000.00 | Form 4 for Bodenhoff Mads (opens sec.gov in a new tab) | |
| Bodenhoff Mads | SVP & PAO | Open-market sale | $810,570.00 | Form 4 for Bodenhoff Mads (opens sec.gov in a new tab) | |
| HOLTUG LARS | Director | Open-market sale | $62,334.59 | Form 4 for HOLTUG LARS (opens sec.gov in a new tab) | |
| BIENAIME JEAN JACQUES | Director | Open-market buy | $270,435.00 | Form 4 for BIENAIME JEAN JACQUES (opens sec.gov in a new tab) | |
| BIENAIME JEAN JACQUES | Director | Open-market buy | $222,219.00 | Form 4 for BIENAIME JEAN JACQUES (opens sec.gov in a new tab) | |
| SMITH SCOTT THOMAS | EVP & Chief Financial Officer | Open-market buy | $21,900.00 | Form 4 for SMITH SCOTT THOMAS (opens sec.gov in a new tab) |
A disclosure, not a signal to trade. Source: SEC EDGAR (Form 4). Older filings and the 90-day buying-and-selling read are part of Pro. See plans
Companies we do put a number on
Not investment advice. TickerWorth Score is a model output.
A descriptive, available-data snapshot and relative comparison — NOT a DCF, NOT a price target, and NOT investment advice. TickerWorth is not a licensed investment adviser, and these figures are estimates from public market data that can be wrong, stale or incomplete.